Frank M Speetjens

7PUBLICATIONS
47CO-AUTHORS
Predictive and prognostic markersHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 28, 2025
Correction: Kalisvaart et al. Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study. Cancers 2024, 16, 1954.

Gijsbert M Kalisvaart, Richard E Evenhuis, Willem Grootjans

|Jul 09, 2025
Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses.

Stefan G van Ravensteijn, Jacco J de Haan, Hans Gelderblom

|May 06, 2025
Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα.

Els M E Verdegaal, Anique L C Verpoorte, Monique K van der Kooij

|Jun 19, 2024
Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study.

Gijsbert M Kalisvaart, Richard E Evenhuis, Willem Grootjans

|Oct 19, 2022
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.

Frank M Speetjens, Marij J P Welters, Marije Slingerland

|Apr 17, 2020
Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma.

Arie Jan Verschoor, Frank M Speetjens, P D Sander Dijkstra

Pageof 2

Frequent Collaborators

4 joint publications

Hans Gelderblom

3 joint publications

Marta Fiocco

3 joint publications

Michiel A J van de Sande

3 joint publications

Judith V M G Bovée